• bit.bio entered an exclusive partnership with Germany’s myriamed to add human iPSC-derived cardiomyocytes to its drug discovery portfolio.
• The deal expands its human cell offering to three key drug-safety organ systems: heart, liver, central nervous system.
• bit.bio will exclusively offer cryopreserved ventricular, atrial cardiomyocytes, including a dilated cardiomyopathy model, for ready-to-plate use.
• The cardiomyocyte suite will also be available through its CRISPR screening services, extending use into phenotypic screening and safety testing.
• Partnership announced on Sept. 23, 2026, positioning the companies for broader adoption of human-relevant models in preclinical testing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bit.bio Ltd. published the original content used to generate this news brief on September 23, 2026, and is solely responsible for the information contained therein.